Listing 1 - 5 of 5 |
Sort by
|
Choose an application
Marine Drugs is glad to announce its first Special Issue book on “ion channels” related research: Under the great stewardship of the Guest Editor, Dr. Jean-Marc Sabatier, four advanced research articles and three comprehensive review papers were collected in the Special Issue “Ion Channels as Marine Drug Targets”. Join us to explore the advanced research outcomes in this field: α-Conotoxin RgIA and a potent analog, RgIA4, in treatment of pain; botulinum toxin-chitosan nanoparticles in treatment of atrial fibrillation; 27-amino acid (aa)-long δ-conotoxin TxVIA that modulates mammalian CaV3.x; first venomics study of Conus tulipa venom; review on marine toxins targeting Kv1 channels; review on synthetic approaches to zetekitoxin AB; and review on marine natural products and drug resistance in latent tuberculosis. The second edition of this Special Issue is open for submissions, we look forward to your contribution.
conotoxin --- Conus tulipa --- intraspecific variation --- venomics --- transcriptomics --- proteomics --- conantokins --- net hunting strategy --- nirvana cabal --- ion channel modulators --- marine anti-TB compounds --- PZA --- MTB --- latent TB --- sponges --- nicotinic --- chemotherapy --- paclitaxel --- taxane --- neuropathic pain --- α9α10 --- saxitoxin --- zetekitoxin AB --- voltage-gated sodium channel --- guanidine alkaloid --- bioactives --- conotoxins 2 --- Kv1 --- marine toxins --- modulators --- potassium channels --- sea anemone toxins --- TxVIA --- mammalian NaV channel --- selective inhibitor --- T-type CaV3.2 --- botulinum toxin A1 --- chitosan nanoparticles --- antiarrhythmics --- pharmacological models of arrhythmia --- electrically induced arrhythmia
Choose an application
Marine Drugs is glad to announce its first Special Issue book on “ion channels” related research: Under the great stewardship of the Guest Editor, Dr. Jean-Marc Sabatier, four advanced research articles and three comprehensive review papers were collected in the Special Issue “Ion Channels as Marine Drug Targets”. Join us to explore the advanced research outcomes in this field: α-Conotoxin RgIA and a potent analog, RgIA4, in treatment of pain; botulinum toxin-chitosan nanoparticles in treatment of atrial fibrillation; 27-amino acid (aa)-long δ-conotoxin TxVIA that modulates mammalian CaV3.x; first venomics study of Conus tulipa venom; review on marine toxins targeting Kv1 channels; review on synthetic approaches to zetekitoxin AB; and review on marine natural products and drug resistance in latent tuberculosis. The second edition of this Special Issue is open for submissions, we look forward to your contribution.
Medicine --- conotoxin --- Conus tulipa --- intraspecific variation --- venomics --- transcriptomics --- proteomics --- conantokins --- net hunting strategy --- nirvana cabal --- ion channel modulators --- marine anti-TB compounds --- PZA --- MTB --- latent TB --- sponges --- nicotinic --- chemotherapy --- paclitaxel --- taxane --- neuropathic pain --- α9α10 --- saxitoxin --- zetekitoxin AB --- voltage-gated sodium channel --- guanidine alkaloid --- bioactives --- conotoxins 2 --- Kv1 --- marine toxins --- modulators --- potassium channels --- sea anemone toxins --- TxVIA --- mammalian NaV channel --- selective inhibitor --- T-type CaV3.2 --- botulinum toxin A1 --- chitosan nanoparticles --- antiarrhythmics --- pharmacological models of arrhythmia --- electrically induced arrhythmia
Choose an application
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and it represents a persistent public health threat for a number of complex biological and sociological reasons. According to the most recent Global Tuberculosis Report (2019) edited by the World Health Organization (WHO), TB is considered the ninth cause of death worldwide and the leading cause of mortality by a single infectious agent, with the highest rate of infections and death toll rate mostly concentrated in developing and low-income countries. We present here the editorial section to the Special Issue entitled “Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment” that includes 7 research articles and a review. The scientific contributions included in the Special Issue mainly focus on the characterization of MTB strains emerging in TB endemic countries as well as on multiple mechanisms adopted by the bacteria to resist and to adapt to antitubercular therapies.
Mycobacterium tuberculosis --- line probe assay --- second-line drugs --- drug resistance --- XDR-TB --- MDR-TB --- omics analysis --- TB treatment --- system analysis --- Beijing B0/W148 --- Mycobacterium smegmatis --- imidazo[1,2-b][1,2,4,5]tetrazine --- MmpS5-MmpL5 --- efflux --- drug discovery --- tuberculosis --- immune activation --- HLA-DR --- CD38 --- treatment response --- Mycobacterium --- macrophage --- apoptosis --- effector --- cytokine --- microRNA --- Beijing genotype --- Central Asia Outbreak --- murine infection model --- Virulence --- pre-XDR-TB --- Mycobacterium avium --- unique metabolic pathways --- subtractive genomics --- drug target --- uncharacterized proteins --- BM-MSCs --- Mtb --- bone-homing --- stem cell niche --- latent tuberculosis --- relapse --- liposomes --- M. tuberculosis --- host-pathogen interactions --- immune response --- antitubercular drug discovery --- antitubercular treatments --- IL-18 --- IL-18BP --- IL-18R --- gene expression
Choose an application
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and it represents a persistent public health threat for a number of complex biological and sociological reasons. According to the most recent Global Tuberculosis Report (2019) edited by the World Health Organization (WHO), TB is considered the ninth cause of death worldwide and the leading cause of mortality by a single infectious agent, with the highest rate of infections and death toll rate mostly concentrated in developing and low-income countries. We present here the editorial section to the Special Issue entitled “Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment” that includes 7 research articles and a review. The scientific contributions included in the Special Issue mainly focus on the characterization of MTB strains emerging in TB endemic countries as well as on multiple mechanisms adopted by the bacteria to resist and to adapt to antitubercular therapies.
Research & information: general --- Biology, life sciences --- Mycobacterium tuberculosis --- line probe assay --- second-line drugs --- drug resistance --- XDR-TB --- MDR-TB --- omics analysis --- TB treatment --- system analysis --- Beijing B0/W148 --- Mycobacterium smegmatis --- imidazo[1,2-b][1,2,4,5]tetrazine --- MmpS5-MmpL5 --- efflux --- drug discovery --- tuberculosis --- immune activation --- HLA-DR --- CD38 --- treatment response --- Mycobacterium --- macrophage --- apoptosis --- effector --- cytokine --- microRNA --- Beijing genotype --- Central Asia Outbreak --- murine infection model --- Virulence --- pre-XDR-TB --- Mycobacterium avium --- unique metabolic pathways --- subtractive genomics --- drug target --- uncharacterized proteins --- BM-MSCs --- Mtb --- bone-homing --- stem cell niche --- latent tuberculosis --- relapse --- liposomes --- M. tuberculosis --- host-pathogen interactions --- immune response --- antitubercular drug discovery --- antitubercular treatments --- IL-18 --- IL-18BP --- IL-18R --- gene expression
Choose an application
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis (MTB) and it represents a persistent public health threat for a number of complex biological and sociological reasons. According to the most recent Global Tuberculosis Report (2019) edited by the World Health Organization (WHO), TB is considered the ninth cause of death worldwide and the leading cause of mortality by a single infectious agent, with the highest rate of infections and death toll rate mostly concentrated in developing and low-income countries. We present here the editorial section to the Special Issue entitled “Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment” that includes 7 research articles and a review. The scientific contributions included in the Special Issue mainly focus on the characterization of MTB strains emerging in TB endemic countries as well as on multiple mechanisms adopted by the bacteria to resist and to adapt to antitubercular therapies.
Research & information: general --- Biology, life sciences --- Mycobacterium tuberculosis --- line probe assay --- second-line drugs --- drug resistance --- XDR-TB --- MDR-TB --- omics analysis --- TB treatment --- system analysis --- Beijing B0/W148 --- Mycobacterium smegmatis --- imidazo[1,2-b][1,2,4,5]tetrazine --- MmpS5-MmpL5 --- efflux --- drug discovery --- tuberculosis --- immune activation --- HLA-DR --- CD38 --- treatment response --- Mycobacterium --- macrophage --- apoptosis --- effector --- cytokine --- microRNA --- Beijing genotype --- Central Asia Outbreak --- murine infection model --- Virulence --- pre-XDR-TB --- Mycobacterium avium --- unique metabolic pathways --- subtractive genomics --- drug target --- uncharacterized proteins --- BM-MSCs --- Mtb --- bone-homing --- stem cell niche --- latent tuberculosis --- relapse --- liposomes --- M. tuberculosis --- host-pathogen interactions --- immune response --- antitubercular drug discovery --- antitubercular treatments --- IL-18 --- IL-18BP --- IL-18R --- gene expression
Listing 1 - 5 of 5 |
Sort by
|